EUCTR2021-005200-35-SE招募中1 期
A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type II
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Participants aged =2 to <6 years (Cohort A) or =6 to <26 years (Cohort B)
- •2. Confirmed diagnosis of MPS II (for Cohort A, nMPS II; for Cohort B, nnMPS II)
- •3. For non-run-in Cohort A and Cohort B only: Be on maintenance ERT and have tolerated a minimum of 4 months (ie, 16 weeks) of idursulfase therapy during the period immediately prior to screening.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 54
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 6
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Have documented pathogenic or likely pathogenic variants that are known to cause developmental delay or decline, cognitive dysfunction, seizures, or other significant CNS disorders.
- •2. Previously received an IDS gene therapy or stem cell therapy
- •3. Received any CNS-targeted MPS ERT within 6 months prior to screening
- •4. Have a contraindication for lumbar punctures and/or magnetic resonance imaging (MRIs)
- •5. Participated in any other investigational drug study or used an investigational drug within 60 days prior to screening or intend to receive another investigational drug during the study
研究者
相似试验
招募中
1 期
Study to determine effectiveness and safety of DNL310 vs Idursulfase in Pediatric Participants With Neuronopathic or Non-Neuronopathic Hunter SyndromeMucopolysaccharidosis Type II [MPS II]MedDRA version: 20.1Level: PTClassification code 10056889Term: Mucopolysaccharidosis IISystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2021-005200-35-ITDenali Therapeutics Inc.54
进行中（未招募）
1 期
Study to determine effectiveness and safety of DNL310 vs Idursulfase in Pediatric Participants With Neuronopathic or Non-Neuronopathic Hunter SyndromeMucopolysaccharidosis Type II [MPS II]EUCTR2021-005200-35-FRDenali Therapeutics Inc.54
招募中
2 期
A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of DNL310 vs Idursulfase in Pediatric Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type IIHunter syndromeMucopolysaccharidosis Type II (MPS II)10029305NL-OMON53946Denali Therapeutics Inc.3
进行中（未招募）
不适用
A Phase 2/3, Multicenter, Double-Blind, Randomized, Controlled Study of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP 2)/Calcium Phosphate Matrix (CPM) in Closed Diaphyseal Tibial FracturesClosed diaphyseal tibial fractureMedDRA version: 8.1Level: LLTClassification code 10043827Term: Tibia fractureEUCTR2006-001831-23-LVWyeth Pharmaceuticals Inc.600
进行中（未招募）
1 期
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa(DNL310) vs Idursulfase in Pediatric and Young Adult ParticipantsWith Neuronopathic or Non Neuronopathic Mucopolysaccharidosis Type IIEUCTR2021-005200-35-BEDenali Therapeutics Inc.54